# **ZOETIS INC.**

ISIN: US98978V1035 WKN: 98978V103 Asset Class: Stock

Company


zoetis

2024/04/26 22:00:02

**Price 158.42**USD

Difference

3.30%(5.06)



#### **Contact Details**

ZOETIS INC. Tel: +1-973-822-7000

-- Fax: +

10 Sylvan Way Web: <a href="http://www.zoetis.com">http://www.zoetis.com</a>

07054 Parsippany E-mail: -

## **Company Profile**

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.

## Financial figures, Fiscal year: from 01.01. to 31.12.

	2023		2022		2021	
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets I	Liabilities and equity
Current assets	6,343,000,000		7,506,000,000		6,930,000,000	
Common stock capital		5,000,000		5,000,000		5,000,000
Fixed assets	7,943,000,000		7,419,000,000		6,970,000,000	
Equity capital of a company		4,991,000,000		4,403,000,000		4,544,000,000
Cash and cash equivalents	2,041,000,000		3,581,000,000		3,485,000,000	
Accrued liabilities		351,000,000		337,000,000		360,000,000
Other assets	-		-		-	
Current liabilities		1,889,000,000		3,167,000,000		1,797,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		7,406,000,000		7,355,000,000		7,559,000,000
Different income		-		-		-
Other liabilities		157,000,000		138,000,000		136,000,000
Total assets	14,286,000,000	14,286,000,000	14,925,000,000	14,925,000,000	13,900,000,000	13,900,000,000

#### **Balance notes**

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	14,100	13,800	12,100
Equity ratio	34.89%	29.49%	32.70%
Debt-equity ratio	186.58%	239.13%	205.83%

#### **Others**

	2023	2022	2021
Tax Expense Rate	20.30%	20.52%	18.25%

# **ZOETIS INC.**

ISIN: US98978V1035 WKN: 98978V103 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	8,544,000,000	8,080,000,000	7,776,000,000
Net income	2,344,000,000	2,114,000,000	2,037,000,000
EBIT	2,912,213,600	2,676,694,400	2,558,934,800
Operating income before taxes	2,936,000,000	2,656,000,000	2,488,000,000
Cash Flow	2,353,000,000	1,912,000,000	2,213,000,000
Net interest income	-180,000,000	-208,000,000	-250,000,000
Research and development expenses	614,000,000	539,000,000	508,000,000
Income taxes	596,000,000	545,000,000	454,000,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	566,328	547,215	600,616

# **Board of Directors**

Members of Management Board		
Michael McCallister	Chairman of Board of Directors	
Linda Rhodes	Member of Board of Directors	
Willie Reed	Member of Board of Directors	
Antoinette Leatherberry	Member of Board of Directors	
Frank D'Amelio	Member of Board of Directors	
Gavin Hattersley	Member of Board of Directors	
Gregory Norden	Member of Board of Directors	
Louise Parent	Member of Board of Directors	
Paul Bisaro	Member of Board of Directors	
Robert Scully	Member of Board of Directors	
Sanjay Khosla	Member of Board of Directors	
Vanessa Broadhurst	Member of Board of Directors	
Kristin Peck	Chairman of Managing Board	
Ester Banque	Member of Executive Committee	
Heidi Chen	Member of Executive Committee	
Jamie Brannan	Member of Executive Committee	
Jeanette Ferran Astorga	Member of Executive Committee	
Nick Ashton	Member of Executive Committee	
Rimma Driscoll	Member of Executive Committee	
Robert J. Polzer	Member of Executive Committee	
Roxanne Lagano	Member of Executive Committee	
Wafaa Mamilli	Member of Executive Committee	
Wetteny Joseph	Member of Executive Committee	